 Ajay Major
Concepts (220)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Large B-Cell, Diffuse | 5 | 2023 | 115 | 2.930 |
Why?
| | Hematologic Neoplasms | 3 | 2025 | 141 | 2.380 |
Why?
| | Multiple Myeloma | 9 | 2024 | 125 | 2.200 |
Why?
| | Hodgkin Disease | 5 | 2025 | 133 | 1.790 |
Why?
| | Lymphoma, Non-Hodgkin | 2 | 2023 | 79 | 1.560 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 13 | 2024 | 1560 | 1.490 |
Why?
| | Medical Oncology | 5 | 2024 | 268 | 1.460 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2022 | 577 | 1.460 |
Why?
| | Neoplasms | 4 | 2022 | 2454 | 1.020 |
Why?
| | Immunotherapy, Adoptive | 3 | 2023 | 300 | 0.900 |
Why?
| | Neoplasm Recurrence, Local | 5 | 2024 | 957 | 0.860 |
Why?
| | Patient Reported Outcome Measures | 2 | 2024 | 374 | 0.850 |
Why?
| | Antibodies, Bispecific | 1 | 2023 | 49 | 0.820 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2025 | 253 | 0.790 |
Why?
| | Lymphoproliferative Disorders | 2 | 2023 | 54 | 0.770 |
Why?
| | Plasma Exchange | 1 | 2021 | 12 | 0.750 |
Why?
| | Purpura, Thrombocytopenic, Idiopathic | 1 | 2021 | 14 | 0.740 |
Why?
| | Vaccination | 2 | 2021 | 1348 | 0.730 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2022 | 126 | 0.720 |
Why?
| | Psychosocial Support Systems | 1 | 2021 | 13 | 0.720 |
Why?
| | Lymphoma, B-Cell | 2 | 2022 | 103 | 0.720 |
Why?
| | Dexamethasone | 7 | 2024 | 352 | 0.710 |
Why?
| | Internship and Residency | 2 | 2021 | 1058 | 0.710 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 1 | 2021 | 29 | 0.700 |
Why?
| | Hospice Care | 1 | 2024 | 194 | 0.700 |
Why?
| | Terminal Care | 1 | 2024 | 216 | 0.690 |
Why?
| | Clinical Trials as Topic | 1 | 2025 | 1005 | 0.680 |
Why?
| | Humans | 54 | 2025 | 129847 | 0.640 |
Why?
| | Drug Costs | 1 | 2020 | 100 | 0.630 |
Why?
| | Quality of Life | 4 | 2024 | 2695 | 0.630 |
Why?
| | Lymphoma, Follicular | 1 | 2019 | 40 | 0.630 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2019 | 87 | 0.620 |
Why?
| | Internal Medicine | 1 | 2021 | 247 | 0.600 |
Why?
| | Neoplasms, Second Primary | 1 | 2019 | 106 | 0.590 |
Why?
| | Brain Neoplasms | 2 | 2017 | 1149 | 0.580 |
Why?
| | Adrenal Insufficiency | 1 | 2018 | 32 | 0.560 |
Why?
| | Lymphoma, Large-Cell, Anaplastic | 1 | 2017 | 19 | 0.540 |
Why?
| | Oncologists | 1 | 2017 | 35 | 0.540 |
Why?
| | Central Nervous System Neoplasms | 3 | 2024 | 149 | 0.530 |
Why?
| | Neoplasm, Residual | 4 | 2024 | 121 | 0.530 |
Why?
| | Mental Health Services | 1 | 2021 | 404 | 0.510 |
Why?
| | Immunocompromised Host | 1 | 2018 | 199 | 0.510 |
Why?
| | Antineoplastic Agents | 2 | 2025 | 2045 | 0.500 |
Why?
| | Medicare | 2 | 2023 | 719 | 0.500 |
Why?
| | Lymphoma | 3 | 2023 | 198 | 0.500 |
Why?
| | Cyclophosphamide | 3 | 2022 | 234 | 0.500 |
Why?
| | Empathy | 1 | 2017 | 170 | 0.480 |
Why?
| | Cancer Survivors | 1 | 2019 | 257 | 0.470 |
Why?
| | Health Personnel | 1 | 2021 | 658 | 0.460 |
Why?
| | Mental Health | 1 | 2021 | 691 | 0.460 |
Why?
| | Students, Medical | 2 | 2021 | 323 | 0.440 |
Why?
| | Hematology | 3 | 2024 | 15 | 0.430 |
Why?
| | Health Services Accessibility | 1 | 2021 | 903 | 0.430 |
Why?
| | Curriculum | 1 | 2020 | 928 | 0.430 |
Why?
| | Bullying | 1 | 2014 | 35 | 0.420 |
Why?
| | Transplantation, Autologous | 3 | 2023 | 213 | 0.410 |
Why?
| | Mental Disorders | 1 | 2021 | 1035 | 0.400 |
Why?
| | Healthcare Disparities | 1 | 2018 | 580 | 0.390 |
Why?
| | Physicians | 1 | 2021 | 875 | 0.390 |
Why?
| | Oligopeptides | 2 | 2024 | 260 | 0.390 |
Why?
| | Aged | 17 | 2025 | 22107 | 0.380 |
Why?
| | Pediatrics | 1 | 2020 | 1074 | 0.380 |
Why?
| | Treatment Outcome | 9 | 2025 | 10241 | 0.380 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2017 | 628 | 0.370 |
Why?
| | Delivery of Health Care | 1 | 2018 | 900 | 0.370 |
Why?
| | Faculty, Medical | 1 | 2014 | 269 | 0.350 |
Why?
| | Education, Medical | 1 | 2014 | 254 | 0.350 |
Why?
| | Middle Aged | 16 | 2025 | 31177 | 0.330 |
Why?
| | Skin Neoplasms | 1 | 2017 | 830 | 0.320 |
Why?
| | Etoposide | 2 | 2021 | 148 | 0.320 |
Why?
| | Vincristine | 2 | 2021 | 108 | 0.310 |
Why?
| | Public Health Surveillance | 2 | 2020 | 68 | 0.310 |
Why?
| | Information Dissemination | 2 | 2022 | 206 | 0.300 |
Why?
| | Male | 20 | 2025 | 63759 | 0.300 |
Why?
| | Aged, 80 and over | 8 | 2024 | 7066 | 0.300 |
Why?
| | Doxorubicin | 2 | 2021 | 329 | 0.290 |
Why?
| | Neoplasm Staging | 3 | 2024 | 1282 | 0.280 |
Why?
| | Fatal Outcome | 2 | 2017 | 300 | 0.260 |
Why?
| | Prognosis | 5 | 2024 | 3773 | 0.260 |
Why?
| | Adult | 13 | 2025 | 35634 | 0.260 |
Why?
| | Databases, Factual | 2 | 2022 | 1269 | 0.240 |
Why?
| | Female | 17 | 2025 | 68829 | 0.240 |
Why?
| | Platelet Factor 4 | 2 | 2022 | 34 | 0.230 |
Why?
| | Young Adult | 7 | 2025 | 12467 | 0.230 |
Why?
| | Disease Management | 2 | 2018 | 592 | 0.220 |
Why?
| | Antibodies, Monoclonal | 2 | 2024 | 1368 | 0.220 |
Why?
| | Rituximab | 2 | 2023 | 164 | 0.220 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2344 | 0.220 |
Why?
| | Methotrexate | 2 | 2023 | 249 | 0.220 |
Why?
| | Lymphoma, T-Cell, Peripheral | 1 | 2024 | 16 | 0.220 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2023 | 77 | 0.210 |
Why?
| | Retrospective Studies | 8 | 2025 | 14553 | 0.210 |
Why?
| | Geriatrics | 1 | 2024 | 81 | 0.200 |
Why?
| | Azacitidine | 1 | 2024 | 137 | 0.200 |
Why?
| | Education, Medical, Graduate | 3 | 2022 | 443 | 0.200 |
Why?
| | Hospices | 1 | 2024 | 86 | 0.200 |
Why?
| | Melphalan | 1 | 2022 | 29 | 0.200 |
Why?
| | Bortezomib | 1 | 2022 | 45 | 0.200 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2024 | 217 | 0.190 |
Why?
| | Watchful Waiting | 1 | 2022 | 67 | 0.190 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 2022 | 33 | 0.190 |
Why?
| | Amyloidosis | 1 | 2022 | 42 | 0.190 |
Why?
| | Africa | 1 | 2022 | 99 | 0.190 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2023 | 95 | 0.190 |
Why?
| | Platelet Count | 1 | 2021 | 82 | 0.190 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2022 | 91 | 0.180 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2021 | 20 | 0.180 |
Why?
| | Fellowships and Scholarships | 2 | 2022 | 279 | 0.170 |
Why?
| | Health Occupations | 1 | 2020 | 30 | 0.170 |
Why?
| | Prednisone | 1 | 2021 | 234 | 0.170 |
Why?
| | Home Care Services | 1 | 2024 | 244 | 0.170 |
Why?
| | Sirolimus | 1 | 2022 | 270 | 0.170 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2025 | 232 | 0.170 |
Why?
| | Sulfonamides | 1 | 2024 | 497 | 0.170 |
Why?
| | Frailty | 1 | 2023 | 152 | 0.170 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2022 | 362 | 0.170 |
Why?
| | Thrombocytopenia | 1 | 2022 | 189 | 0.160 |
Why?
| | Blood Coagulation Disorders | 1 | 2022 | 167 | 0.160 |
Why?
| | Survivorship | 1 | 2020 | 47 | 0.160 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2022 | 398 | 0.160 |
Why?
| | Botulism | 1 | 2019 | 6 | 0.160 |
Why?
| | Personal Satisfaction | 1 | 2021 | 204 | 0.150 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 5437 | 0.150 |
Why?
| | Medical Informatics | 1 | 2020 | 99 | 0.150 |
Why?
| | Program Development | 1 | 2021 | 355 | 0.150 |
Why?
| | Heroin Dependence | 1 | 2019 | 31 | 0.150 |
Why?
| | Pandemics | 3 | 2022 | 1500 | 0.150 |
Why?
| | SEER Program | 1 | 2019 | 202 | 0.150 |
Why?
| | Neoplasm Grading | 1 | 2019 | 283 | 0.150 |
Why?
| | Artificial Intelligence | 1 | 2021 | 245 | 0.150 |
Why?
| | Education, Medical, Undergraduate | 1 | 2021 | 179 | 0.150 |
Why?
| | Risk Factors | 4 | 2024 | 9801 | 0.150 |
Why?
| | Needs Assessment | 1 | 2020 | 357 | 0.150 |
Why?
| | Social Media | 1 | 2020 | 141 | 0.140 |
Why?
| | Substance Abuse, Intravenous | 1 | 2019 | 109 | 0.140 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2024 | 596 | 0.140 |
Why?
| | Immunosuppressive Agents | 2 | 2023 | 858 | 0.140 |
Why?
| | Prednisolone | 1 | 2017 | 82 | 0.140 |
Why?
| | Mediastinal Neoplasms | 1 | 2017 | 39 | 0.140 |
Why?
| | Symptom Assessment | 1 | 2018 | 125 | 0.130 |
Why?
| | Narration | 1 | 2017 | 57 | 0.130 |
Why?
| | Vaccines | 1 | 2022 | 400 | 0.130 |
Why?
| | Machine Learning | 1 | 2021 | 441 | 0.130 |
Why?
| | Research | 1 | 2020 | 420 | 0.130 |
Why?
| | Program Evaluation | 1 | 2021 | 878 | 0.130 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2022 | 756 | 0.130 |
Why?
| | Immunotherapy | 1 | 2021 | 596 | 0.130 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 851 | 0.130 |
Why?
| | Adaptation, Psychological | 1 | 2021 | 618 | 0.130 |
Why?
| | Survivors | 1 | 2019 | 464 | 0.130 |
Why?
| | Pilot Projects | 1 | 2021 | 1597 | 0.120 |
Why?
| | Burnout, Professional | 1 | 2022 | 411 | 0.120 |
Why?
| | Proportional Hazards Models | 1 | 2018 | 1199 | 0.120 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2017 | 231 | 0.120 |
Why?
| | Combined Modality Therapy | 1 | 2018 | 1201 | 0.120 |
Why?
| | Anxiety | 1 | 2021 | 976 | 0.110 |
Why?
| | Adolescent | 4 | 2025 | 20451 | 0.110 |
Why?
| | Attitude of Health Personnel | 1 | 2021 | 1106 | 0.100 |
Why?
| | Clinical Competence | 1 | 2020 | 1020 | 0.100 |
Why?
| | Mutation | 1 | 2024 | 3706 | 0.100 |
Why?
| | United States | 4 | 2025 | 13913 | 0.100 |
Why?
| | Child | 3 | 2022 | 20962 | 0.100 |
Why?
| | Cytokines | 1 | 2021 | 2022 | 0.100 |
Why?
| | Stress, Psychological | 1 | 2021 | 1070 | 0.100 |
Why?
| | T-Lymphocytes | 1 | 2021 | 1937 | 0.100 |
Why?
| | Age Factors | 1 | 2020 | 3161 | 0.100 |
Why?
| | Registries | 1 | 2020 | 1903 | 0.100 |
Why?
| | Depression | 1 | 2021 | 1323 | 0.090 |
Why?
| | Cell Differentiation | 1 | 2019 | 1900 | 0.090 |
Why?
| | Prevalence | 1 | 2018 | 2564 | 0.090 |
Why?
| | Colorado | 1 | 2021 | 4410 | 0.090 |
Why?
| | Electronic Health Records | 1 | 2017 | 979 | 0.080 |
Why?
| | Recurrence | 2 | 2024 | 1013 | 0.070 |
Why?
| | Maintenance Chemotherapy | 1 | 2024 | 22 | 0.060 |
Why?
| | Lymphoma, Extranodal NK-T-Cell | 1 | 2024 | 9 | 0.060 |
Why?
| | Lymphoma, T-Cell | 1 | 2024 | 23 | 0.060 |
Why?
| | Withholding Treatment | 1 | 2024 | 71 | 0.060 |
Why?
| | Thalidomide | 1 | 2024 | 32 | 0.050 |
Why?
| | Cytarabine | 1 | 2023 | 57 | 0.050 |
Why?
| | Cell Transplantation | 1 | 2023 | 37 | 0.050 |
Why?
| | Imides | 1 | 2022 | 10 | 0.050 |
Why?
| | Proteasome Inhibitors | 1 | 2022 | 42 | 0.050 |
Why?
| | Congresses as Topic | 1 | 2024 | 216 | 0.050 |
Why?
| | Frail Elderly | 1 | 2023 | 120 | 0.050 |
Why?
| | Biotin | 1 | 2022 | 23 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2023 | 157 | 0.050 |
Why?
| | Academic Medical Centers | 1 | 2025 | 483 | 0.050 |
Why?
| | Injections, Spinal | 1 | 2022 | 111 | 0.050 |
Why?
| | Education, Premedical | 1 | 2021 | 4 | 0.050 |
Why?
| | Geriatric Assessment | 1 | 2023 | 205 | 0.050 |
Why?
| | Blogging | 1 | 2021 | 6 | 0.050 |
Why?
| | Blood Component Transfusion | 1 | 2022 | 83 | 0.050 |
Why?
| | Polymerase Chain Reaction | 1 | 2024 | 1033 | 0.040 |
Why?
| | Professionalism | 1 | 2021 | 18 | 0.040 |
Why?
| | Killer Cells, Natural | 1 | 2024 | 426 | 0.040 |
Why?
| | Central Nervous System | 1 | 2023 | 256 | 0.040 |
Why?
| | Heparin | 1 | 2022 | 254 | 0.040 |
Why?
| | Plasma | 1 | 2022 | 206 | 0.040 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2025 | 753 | 0.040 |
Why?
| | Societies, Medical | 1 | 2024 | 759 | 0.040 |
Why?
| | Lymphocytes | 1 | 2022 | 377 | 0.040 |
Why?
| | Activities of Daily Living | 1 | 2023 | 384 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2021 | 374 | 0.040 |
Why?
| | Writing | 1 | 2021 | 91 | 0.040 |
Why?
| | Blood Transfusion | 1 | 2022 | 298 | 0.040 |
Why?
| | Lymph Nodes | 1 | 2022 | 471 | 0.040 |
Why?
| | Dysphonia | 1 | 2019 | 13 | 0.040 |
Why?
| | Drug Contamination | 1 | 2019 | 51 | 0.040 |
Why?
| | Paraplegia | 1 | 2019 | 57 | 0.040 |
Why?
| | Muscle Weakness | 1 | 2019 | 85 | 0.040 |
Why?
| | Diagnostic Errors | 1 | 2019 | 162 | 0.040 |
Why?
| | Biomedical Research | 1 | 2024 | 640 | 0.040 |
Why?
| | Deglutition Disorders | 1 | 2019 | 133 | 0.030 |
Why?
| | Dyspnea | 1 | 2019 | 239 | 0.030 |
Why?
| | Hepatitis C, Chronic | 1 | 2019 | 156 | 0.030 |
Why?
| | Incidence | 1 | 2023 | 2646 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 282 | 0.030 |
Why?
| | Risk Assessment | 1 | 2023 | 3269 | 0.030 |
Why?
| | Cohort Studies | 1 | 2023 | 5444 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 5085 | 0.020 |
Why?
|
|
Major's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|